Role of AKT and PI3K Inhibitors in Patients With HR-Positive Breast Cancers: Experts Share Their Thoughts on Current Practice and Future Opportunities

Podcast with global experts discussing the role of AKT and PI3K inhibitors in patients with resistance to endocrine therapy in the adjuvant or metastatic disease settings following current guidelines, indications, and best clinical practices.

Presenters:

Nadia Harbeck, MD
Breast Cancer Director
Department of OB&GYN and Comprehensive Cancer Center Munich
LMU University Hospital
Munich, Germany

Francois-Clement Bidard, MD, PhD
Breast Medical Oncology
Institut Curie & University of Versailles
Paris, France

Link to full program:
https://bit.ly/4cFd0Xj

Get access to all our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.